Last reviewed · How we verify
NCT03789357
Prevalence of Primary Aldosteronism in Patients With Stroke
trial testing Aldosterone renin ratio in Primary Aldosteronism in 300 participants. Completed in 30 September 2021.
31 July 2021
Quick facts
| Lead sponsor | Changi General Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 May 2018 |
| Primary completion | 31 July 2021 |
| Estimated completion | 30 September 2021 |
| Sites | 1 location across Singapore |
Drugs / interventions tested
- Aldosterone renin ratio
Conditions studied
- Primary Aldosteronism — all drugs for Primary Aldosteronism →
- Stroke — all drugs for Stroke →
Sponsor
Changi General Hospital
Who can join
Adults 21 to 80, any sex, with Primary Aldosteronism or Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Strokes leads to significant morbidity and mortality, and hypertension is the most important risk factor for strokes. It is estimated that up to 10% of patients with hypertension have the underlying, treatable condition of primary aldosteronism. Hence, we hypothesize that the prevalence of primary aldosteronism is high in patients with strokes, a complication of long-standing hypertension. Patients admitted with an acute stroke to the Acute Stroke Unit, Changi General Hospital, will be screened for Primary Aldosteronism three months post-stroke, and confirmatory tests will be done with saline-infusion test.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03789357
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Primary Aldosteronism
Currently open trials in the same condition.
- NCT07298954 — Sequential Combined Versus Single-Strategy Adrenal Venous Sampling for Primary Aldosteronism(SCOPE) · NA · recruiting
- NCT07111351 — Multi-omics Studies of Primary Aldosteronism · recruiting
- NCT07027254 — PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism · NA · recruiting
- NCT06941116 — Steroids-Based Screening for Primary Aldosteronism · recruiting
- NCT06955286 — Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Witho · recruiting
Other Changi General Hospital trials
Trials by the same sponsor.
- NCT07297745 — Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA) · NA · not yet recruiting
- NCT07205133 — A Randomized Controlled Trial Comparing Whole Body Vibration Therapy With Usual Care and Usual Care to Improve Muscle He · NA · recruiting
- NCT06970717 — Programmable Smart Watch for Remote Pre-habilitation/Rehabilitation Monitoring · NA · not yet recruiting
- NCT06890169 — OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities · NA · recruiting
- NCT06304415 — Elevated Lipoprotein(a) in Hospital Staff · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03789357 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changi General Hospital
- Last refreshed: 20 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03789357.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing